Omda (OMDA) Aktienübersicht
Omda AS bietet Softwarelösungen für den Gesundheitssektor in Norwegen, Schweden, Dänemark, Finnland und international an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
OMDA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omda AS Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | NOK 34.40 |
| 52-Wochen-Hoch | NOK 56.60 |
| 52-Wochen-Tief | NOK 33.00 |
| Beta | 0.45 |
| 1 Monat Veränderung | -17.11% |
| 3 Monate Veränderung | -11.57% |
| 1 Jahr Veränderung | -35.09% |
| 3 Jahre Veränderung | -28.18% |
| 5 Jahre Veränderung | -61.95% |
| Veränderung seit IPO | -58.55% |
Aktuelle Nachrichten und Updates
Narrativ-Update • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Narrativ-Update • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Recent updates
Narrativ-Update • May 10
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Drive Future Upside Potential
Analysts now place Omda's fair value at NOK 57.0, with the updated price target shaped by refreshed discount rate assumptions and recent mixed but generally constructive research commentary on guidance, growth drivers and valuation in the sector. Analyst Commentary Recent research on Omda reflects an active debate on how to balance strong reported execution with more cautious valuation and guidance assumptions.Narrativ-Update • Apr 20
OMDA: Q4 Execution And 2026 Guidance Conservatism Will Support Upside Potential
Analysts have adjusted their Omda price target to NOK57.0, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions after recent research highlighted both reduced targets across several firms and continued confidence in Omda's growth runway and program momentum. Analyst Commentary Street research around Omda presents a mix of recalibrated price targets and continued confidence in the company’s ability to execute on its program pipeline.Narrativ-Update • Apr 06
OMDA: Q4 Outperformance And 2026 Guidance Conservatism Are Expected To Drive Upside
The updated analyst price target for Omda now reflects a more cautious tone seen across recent NOK-based targets, as analysts factor in refreshed models following Q4 results, revised guidance and ongoing debate around how conservative the medium-term outlook might be. Analyst Commentary Street research on Omda clusters around lowered price targets in the near term, but most firms are maintaining positive or neutral ratings, pointing to a mix of execution momentum and valuation questions.Narrativ-Update • Mar 23
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Drive Upside
Analysts have trimmed the Omda fair value estimate from NOK 59 to NOK 57, reflecting updated price targets and modeling that factors in revised profit margin expectations, alongside supportive views on revenue growth and the broader program momentum flagged in recent research notes. Analyst Commentary Recent Street research on Omda points to a reset in expectations around valuation, while still highlighting execution on growth initiatives and Q4 performance.Narrativ-Update • Mar 08
OMDA: Multi Condition Momentum And 2026 Guidance Are Expected To Unlock Upside
Analysts have nudged our Omda price target slightly lower to NOK 59.0, reflecting modestly higher discount rate and P/E assumptions while still citing solid Q4 execution, program momentum and a generally supportive tone across recent research updates. Analyst Commentary Recent research paints a mixed but generally constructive picture around Omda, with most firms trimming price targets while still pointing to solid execution and program traction after Q4.Narrativ-Update • Feb 22
OMDA: Cardiometabolic Partnerships And Reduced Multiple Are Expected To Unlock Upside
Analysts have trimmed their Omda price targets by about NOK 3, reflecting slightly higher discount rate assumptions and a lower future P/E multiple, as they balance growth expectations with recent stock performance and client concentration risks. Analyst Commentary Recent Street research on Omda highlights a mix of optimism around the core business and caution around how that story translates into valuation and execution risk.Narrativ-Update • Feb 07
OMDA: Cardiometabolic Program Expansion And AI Platform Investment Will Drive Future Upside
Analysts have trimmed their average price targets on Omda by a few dollars, reflecting a slightly higher discount rate and a modestly higher assumed future P/E, while still pointing to a mix of growth opportunities in cardiometabolic programs and client concentration risks. Analyst Commentary Recent research on Omda reflects a mix of optimism around long term growth potential and caution around execution and concentration risks.Narrativ-Update • Jan 24
OMDA: GLP-1 Companion Expansion And AI Investment Will Drive Future Upside
Analysts have trimmed their blended price target for Omda by a few dollars to align with recent cuts and initiations around the $17 to $32 range, citing a combination of strong GLP-1 related momentum, partnership tailwinds, revenue growth potential, and concerns about client concentration and ownership complexity. Analyst Commentary Recent research on Omda reflects a mix of optimism around growth drivers and caution around concentration risks and ownership structure, which together help frame how analysts think about valuation and execution risk.Narrativ-Update • Jan 10
OMDA: Cardiometabolic Platform Expansion And AI Execution Will Support Future Upside Potential
Analysts have slightly adjusted their outlook on Omda, with a modest change in the implied fair value and Street price targets. This reflects updated views on discount rates, long term growth drivers, and mixed recent research that includes lower targets from Goldman Sachs and Wells Fargo, alongside more constructive targets from BMO Capital and Morgan Stanley.Narrativ-Update • Dec 22
OMDA: Expanded GLP-1 Programs And AI Offerings Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00, supported by expectations for sustained revenue growth above 20%, expanding margins, and accelerating adoption of its enhanced GLP-1 programs and AI driven offerings. Analyst Commentary Recent Street research reflects a predominantly constructive stance on Omda, with bullish analysts highlighting a combination of strong execution, favorable unit economics, and a long runway for growth as key drivers of upside to the newly raised price target.Narrativ-Update • Dec 08
OMDA: GLP 1 Program Expansion Will Drive Future Margin Upside
Analysts have raised their price target on Omda to $59.00 per share from a previously implied lower level, citing expectations for sustained 20% plus revenue growth, expanding margins, and accelerating GLP 1 related momentum as key drivers of upside. Analyst Commentary Recent Street commentary highlights a constructive backdrop for Omda, with bullish analysts pointing to a long runway for growth supported by a large, under-penetrated market, strong execution, and accelerating GLP 1 related initiatives.Narrativ-Update • Nov 24
OMDA: Expanding Market And AI Integration Will Drive Continued Growth Momentum
Analysts have significantly raised Omda's fair value estimate from $35 to $59. They cite strong revenue growth, improved profit margins, an expanding addressable market, and increased momentum in new product rollouts and profitability.Analyseartikel • Oct 10
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Narrativ-Update • Aug 23
M&A And Competition Will Shape Risk And Opportunity In Healthcare
Despite Omada’s stronger-than-expected growth in members and revenue, robust gross margin gains, and improving clinical partnerships, analysts have lowered the price target from NOK44.00 to NOK35.00 due to a more cautious broader outlook. Analyst Commentary Bullish analysts highlight Omada’s member and revenue growth significantly surpassing expectations, with first-quarter figures beating estimates by 6.7% and 11.5%, respectively.Analyseartikel • May 23
Omda AS (OB:OMDA) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Omda AS ( OB:OMDA ) shares have been powering on, with a gain of 32% in the last thirty...Analyseartikel • May 16
These 4 Measures Indicate That Omda (OB:OMDA) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Neues Narrativ • May 08
Restructuring, Acquisitions And AI Integration Will Secure Operational Efficiency
Restructuring completion and an enhanced acquisition strategy are expected to boost operational efficiency, revenue growth, and earnings.Analyseartikel • Apr 08
Little Excitement Around Omda AS' (OB:OMDA) Revenues
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy right now compared to the...Analyseartikel • Jan 26
Omda (OB:OMDA) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analyseartikel • Dec 21
The Market Doesn't Like What It Sees From Omda AS' (OB:OMDA) Revenues Yet
Omda AS' ( OB:OMDA ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a buy right now compared to the...Analyseartikel • Nov 13
Returns On Capital Are Showing Encouraging Signs At Omda (OB:OMDA)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...Analyseartikel • Jul 24
Returns At Omda (OB:OMDA) Are On The Way Up
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analyseartikel • May 22
Omda's (OB:OMDA) Earnings Are Weaker Than They Seem
Despite posting some strong earnings, the market for Omda AS' ( OB:OMDA ) stock hasn't moved much. Our analysis...Analyseartikel • Mar 24
Improved Revenues Required Before Omda AS (OB:OMDA) Stock's 28% Jump Looks Justified
Omda AS ( OB:OMDA ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month...Analyseartikel • Jan 24
Fewer Investors Than Expected Jumping On Omda AS (OB:OMDA)
When close to half the companies operating in the Healthcare Services industry in Norway have price-to-sales ratios (or...Analyseartikel • Nov 18
Omda's (OB:OMDA) Earnings May Just Be The Starting Point
Omda AS ( OB:OMDA ) recently posted some strong earnings, and the market responded positively. We have done some...Analyseartikel • Jun 17
Are Investors Undervaluing CSAM Health Group AS (OB:CSAM) By 44%?
Key Insights The projected fair value for CSAM Health Group is kr81.03 based on 2 Stage Free Cash Flow to Equity CSAM...Aktionärsrenditen
| OMDA | NO Healthcare Services | NO Markt | |
|---|---|---|---|
| 7D | -9.5% | 3.6% | 3.2% |
| 1Y | -35.1% | -10.2% | 24.9% |
Rendite im Vergleich zur Industrie: OMDA unter dem Niveau der Branche Norwegian Healthcare Services , die im vergangenen Jahr eine Rendite von -10.2% erzielte.
Rendite vs. Markt: OMDA hinter dem Markt Norwegian zurück, der im vergangenen Jahr eine Rendite von 24.9 erzielte.
Preisvolatilität
| OMDA volatility | |
|---|---|
| OMDA Average Weekly Movement | 7.1% |
| Healthcare Services Industry Average Movement | 6.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in NO Market | 12.4% |
| 10% least volatile stocks in NO Market | 3.3% |
Stabiler Aktienkurs: OMDA hatte in den letzten 3 Monaten im Vergleich zum Norwegian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: OMDADie wöchentliche Volatilität (7%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1999 | 255 | Sverre Flatby | omda.com |
Omda AS bietet Softwarelösungen für den Gesundheitssektor in Norwegen, Schweden, Dänemark, Finnland und international an. Das Unternehmen bietet Laborinformationsmanagementsysteme, bestehend aus Omda ProSang, einem Blut-, Zell- und Gewebemanagementsystem, und medizinische Medikationslösungen, bestehend aus Omda Cytodose, einer onkologischen Behandlungsmanagementlösung. Das Unternehmen bietet auch vernetzte Gesundheitslösungen an, darunter Omda Cardio, ein EKG- und Diagnosespeicherungstool; Omda CIMA, eine mobile App für die medizinische Bildgebung; Omda Media, eine webbasierte Lösung für die medizinische Bildgebung; Omda Medimaker, ein Bildmanagement- und Workflow-System; Omda Picsara, eine Bildmanagement-Lösung; Omda Arcidis, ein integriertes Teleradiologiesystem; Omda Helsemail, ein Tool für die Übertragung von Patientendaten; Omda Plutus, eine Audit- und Workflow-Überwachungsplattform; Omda S7, eine sichere E-Care-Kommunikationsplattform; und Omda XDS, eine Lösung für die Speicherung und Verwaltung von Patientendaten.
Omda AS's Grundlagenzusammenfassung
| OMDA grundlegende Statistiken | |
|---|---|
| Marktanteil | NOK 705.46m |
| Gewinn(TTM) | -NOK 35.92m |
| Umsatz(TTM) | NOK 493.60m |
1.4x
Kurs-Umsatz-Verhältnis-19.6x
Kurs-Gewinn-Verhältnis Ist OMDA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| OMDA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | NOK 493.60m |
| Kosten der Einnahmen | NOK 258.75m |
| Bruttogewinn | NOK 234.85m |
| Sonstige Ausgaben | NOK 270.77m |
| Gewinn | -NOK 35.92m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 27, 2026
| Gewinn per Aktie (EPS) | -1.75 |
| Bruttomarge | 47.58% |
| Nettogewinnspanne | -7.28% |
| Schulden/Eigenkapital-Verhältnis | -2,394.2% |
Wie hat sich OMDA auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
1.4%
Aktuelle Dividendenrendite146%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 03:07 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Omda AS wird von 3 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Kristian Støle | Carnegie Investment Bank AB |
| Emilie Engen | DNB Carnegie |
| Eirik Rafdal | DNB Carnegie |